SRNE - Sorrento-partnered cancer drug shows favorable effects in Phase 1 study

Photo by AlexanderFord/E+ via Getty Images Sorrento Therapeutics (SRNE) announced that HER2-ADC, A166 an experimental breast cancer therapy developed in partnership with Kelun-Biotech indicated a “better safety profile” and “potentially better efficacy” in a Phase 1 study in a type of breast cancer. Kelun-Biotech is set to present data at the ongoing American Society of Clinical Oncology ((ASCO)) meeting. A166, a site-specific third-generation antibody-drug conjugate ((ADC)) was developed by Kelun in partnership with Levena Biopharma, a subsidiary of Sorrento. As for efficacy, in HER2-positive breast cancer, A166 has demonstrated an overall response rate ((ORR)) of 71.4% (A166) at 6.0 mg/kg versus a major competitor, DS-8201, which had an ORR of 60.9% (DS-8201) at 5.4 mg/kg. Today, Sorrento signed an agreement with a Swedish entity targeting the development of cell-based therapeutics using natural killer cells based on induced pluripotent stem cells. #ASCO21

For further details see:

Sorrento-partnered cancer drug shows favorable effects in Phase 1 study